Comparison of Montreal Cognitive Assessment test and Mini Mental State Examination in detecting cognitive impairment in relapsing-remitting multiple sclerosis patients
International Clinical Neuroscience Journal,
Vol. 2 No. 4 (2015),
5 May 2016
Background and purpose: Cognitive impairment (CI) is one of the causes of disabilities in multiple sclerosis patients (MS). Therefore, early detection and evaluation of cognitive performance is very important in patients with MS. The aim of the present study is to compare Montreal Cognitive Assessment (MoCA) test and Mini Mental Status Exam (MMSE) in Relapsing Remitting (RR) MS patients.
Methods: Fifty RRMS patients who met inclusion and exclusion criteria were recruited in this study. MMSE and MoCA were administrated to all subjects. Also demographic data, disease duration and EDSS were recorded. The results of both tests were compared.
Results: The mean score of MoCA and MMSE was 22.86±3.85 and 27.64±2, with a significant difference (p<0.0005). With using MoCA 60% of subject had CI, whereas with MMSE only 34% were impaired (p<0.0005). There was an inverse significant association between education and CI detected by both MMSE and MoCA (for MMSE r=0.535 and p<0.0005, for MoCA r=0.544 and p<0.0005). A significant association was also found between disease duration and CI on both tests (for MMSE r=0.394 and p<0.0005, for MoCA r=0.538 and p<0.0005).
Conclusion: This study suggests that the MoCA has superiority to the MMSE for evaluating cognitive function in RRMS patients.
- Cognitive Impairment
- Montreal Cognitive Assessment
- Mini Mental Status Exam
- Multiple Sclerosis
- Relapsing Remitting
How to Cite
Borghi M, Cavallo M, Carletto S, Ostacoli L, Zuffranieri M, Picci RL, et al. Presence and significant determinants of cognitive impairment in a large sample of patients with multiple sclerosis. PloS one. 2013;8(7).
Planas R, Martin R, Sospedra M. Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life. Patient related outcome measures. 2014;5:25.
Rogers JM, Panegyres PK. Cognitive impairment in multiple sclerosis: evidence-based analysis and recommendations. Journal of Clinical Neuroscience. 2007;14(10):919-27.
Smith T, Gildeh N, Holmes C. The Montreal Cognitive Assessment: validity and utility in a memory clinic setting. Canadian Journal of Psychiatry. 2007;52(5):329.
Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society. 2005;53(4):695-9.
Nazem S, Siderowf AD, Duda JE, Ten Have T, Colcher A, Horn SS, et al. Montreal Cognitive Assessment Performance in Patients with Parkinson's Disease with “Normal” Global Cognition According to Mini‐Mental State Examination Score. Journal of the American Geriatrics Society. 2009;57(2):304-8.
Prakash R, Snook E, Lewis J, Motl R, Kramer A. Cognitive impairments in relapsing-remitting multiple sclerosis: a meta-analysis. Multiple Sclerosis. 2008;14(9):1250-61.
Lee J-Y, Lee DW, Cho S-J, Na DL, Jeon HJ, Kim S-K, et al. Brief screening for mild cognitive impairment in elderly outpatient clinic: validation of the Korean version of the Montreal Cognitive Assessment. Journal of Geriatric Psychiatry and Neurology. 2008;21(2):104-10.
Amato MP, Zipoli V, Portaccio E. Cognitive changes in multiple sclerosis. 2008.
Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Annals of neurology. 2005;58(6):840-6.
Kurtzke JF. Rating neurologic impairment in multiple sclerosis an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-.
Bour A, Rasquin S, Boreas A, Limburg M, Verhey F. How predictive is the MMSE for cognitive performance after stroke? Journal of neurology. 2010;257(4):630-7.
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. Journal of psychiatric research. 1975;12(3):189-98.
Hoops S, Nazem S, Siderowf A, Duda J, Xie S, Stern M, et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology. 2009;73(21):1738-45.
Sikaroodi H, Yadegari S, Miri SR. Cognitive impairments in patients with cerebrovascular risk factors: a comparison of Mini Mental Status Exam and Montreal Cognitive Assessment. Clinical neurology and neurosurgery. 2013;115(8):1276-80.
Freitas S, Simões MR, Alves L, Santana I. Montreal cognitive assessment: validation study for mild cognitive impairment and Alzheimer disease. Alzheimer Disease & Associated Disorders. 2013;27(1):37-43.
Dagenais E, Rouleau I, Demers M, Jobin C, Roger É, Chamelian L, et al. Value of the MoCA test as a screening instrument in multiple sclerosis. The Canadian Journal of Neurological Sciences. 2013;40(03):410-5.
Kaur D, Kumar G, Singh AK. Quick screening of cognitive function in Indian multiple sclerosis patients using Montreal cognitive assessment test-short version. Annals of Indian Academy of Neurology. 2013;16(4):585.
Beatty WW, Aupperle RL. Sex differences in cognitive impairment in multiple sclerosis. The Clinical Neuropsychologist. 2002;16(4):472-80.
Leclercq E, Cabaret M, Guilbert A, Jougleux C, Vermersch P, Moroni C. The influence of age and illness duration on cognitive impairment in aging patients with relapsing-remitting multiple sclerosis (RR-MS). Geriatrie et psychologie neuropsychiatrie du vieillissement. 2014;12(3):331-8.
Gontkovsky ST. Influence of IQ in interpreting MMSE scores in patients with multiple sclerosis. Aging, Neuropsychology, and Cognition. 2014;21(2):214-21.
- Abstract Viewed: 336 times
- PDF Downloaded: 1555 times